Seattle Genetics Inc. (SGEN)

68.32
0.71 1.00
NASDAQ : Health Technology
Prev Close 69.03
Open 68.93
Day Low/High 68.16 / 70.22
52 Wk Low/High 50.71 / 84.37
Volume 184.13K
Avg Volume 826.60K
Exchange NASDAQ
Shares Outstanding 161.31M
Market Cap 11.40B
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Seattle Genetics Announces Additional Analyses Of ECHELON-1 And ECHELON-2 Phase 3 Clinical Trials Of ADCETRIS® (Brentuximab Vedotin) At The 2019 ASCO Annual Meeting

Seattle Genetics Announces Additional Analyses Of ECHELON-1 And ECHELON-2 Phase 3 Clinical Trials Of ADCETRIS® (Brentuximab Vedotin) At The 2019 ASCO Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced additional analyses of results from ECHELON-1 and ECHELON-2, the frontline phase 3 trials of ADCETRIS ® (brentuximab vedotin), at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting...

Astellas And Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate Of 44 Percent In Patients With Most Common Type Of Advanced Urothelial (Bladder) Cancer

Astellas And Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate Of 44 Percent In Patients With Most Common Type Of Advanced Urothelial (Bladder) Cancer

-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-

Robin G. Taylor, M.B.A., Ph.D., Chief Commercial Officer At Seattle Genetics (Photo: Business Wire)

Robin G. Taylor, M.B.A., Ph.D., Chief Commercial Officer At Seattle Genetics (Photo: Business Wire)

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of Robin G.

Seattle Genetics Announces Presentations Of New Clinical Data From Multiple Studies Of Novel Targeted Therapies At The American Society Of Clinical Oncology (ASCO) Annual Meeting

Seattle Genetics Announces Presentations Of New Clinical Data From Multiple Studies Of Novel Targeted Therapies At The American Society Of Clinical Oncology (ASCO) Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from six of its proprietary programs will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting taking place May 31 to June 4, 2019 in Chicago.

Seattle Genetics To Present At RBC Capital Markets 2019 Global Healthcare Conference

Seattle Genetics To Present At RBC Capital Markets 2019 Global Healthcare Conference

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the RBC Capital Markets 2019 Global Healthcare Conference on Wednesday, May 22, 2019 at 8:30 a.

Seattle Genetics Announces Progress In Expanding ADCETRIS® (Brentuximab Vedotin) Indications In Canada

Seattle Genetics Announces Progress In Expanding ADCETRIS® (Brentuximab Vedotin) Indications In Canada

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Health Canada has approved the supplemental New Drug Submission that expands the use of ADCETRIS (brentuximab vedotin) in combination with AVD (Adriamycin, vinblastine and dacarbazine) chemotherapy...

Seattle Genetics Reports First Quarter 2019 Financial Results

Seattle Genetics Reports First Quarter 2019 Financial Results

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the first quarter ended March 31, 2019.

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter 2019 Financial Results On April 25, 2019

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter 2019 Financial Results On April 25, 2019

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets.

Seattle Genetics Completes Enrollment In Phase 2 Clinical Trial Of Tisotumab Vedotin In Recurrent Or Metastatic Cervical Cancer

Seattle Genetics Completes Enrollment In Phase 2 Clinical Trial Of Tisotumab Vedotin In Recurrent Or Metastatic Cervical Cancer

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced completion of enrollment in the potentially pivotal innovaTV 204 phase 2 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent...

Seattle Genetics To Host Conference Call On Positive Topline Results From Pivotal Trial Of Enfortumab Vedotin

Seattle Genetics To Host Conference Call On Positive Topline Results From Pivotal Trial Of Enfortumab Vedotin

Seattle Genetics, Inc. (Nasdaq:SGEN) will host a conference call and webcast discussion regarding the positive topline results from its pivotal clinical trial of enfortumab vedotin in locally advanced or metastatic urothelial cancer, which were announced...

Seattle Genetics Highlights Antibody-Drug Conjugate Innovation And Immuno-Oncology Program At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics Highlights Antibody-Drug Conjugate Innovation And Immuno-Oncology Program At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data highlights from six presentations showcasing technology advances in the company's antibody-drug conjugate (ADC) platform and an immuno-oncology program at the American Association for Cancer...

Seattle Genetics To Present At Cowen And Company 39th Annual Health Care Conference

Seattle Genetics To Present At Cowen And Company 39th Annual Health Care Conference

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, March 12, 2019 at 10:40 a.

Seattle Genetics Achieves $30 Million Milestone Payment For European Commission Approval Of ADCETRIS® (Brentuximab Vedotin) In Frontline Hodgkin Lymphoma

Seattle Genetics Achieves $30 Million Milestone Payment For European Commission Approval Of ADCETRIS® (Brentuximab Vedotin) In Frontline Hodgkin Lymphoma

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing authorization for ADCETRIS (brentuximab vedotin) to include ADCETRIS...

Seattle Genetics Reports Fourth Quarter And Full Year 2018 Financial Results

Seattle Genetics Reports Fourth Quarter And Full Year 2018 Financial Results

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2018.

Seattle Genetics To Present At Guggenheim Healthcare Talks Idea Forum | Oncology Day

Seattle Genetics To Present At Guggenheim Healthcare Talks Idea Forum | Oncology Day

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Guggenheim Healthcare Talks Idea Forum | Oncology Day on Thursday, February 14, 2019 at 2:00 p.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, DGII, FLWS, JVA, LBRDA, MUR, OLP, RDY, SGEN, TESS, TWIN, VMC, YRCW Downgrades: CRUS, MINI, USLM, ZBH Initiations: CBTX, MBIN, SOGO Read on to get TheStreet Quant Ratings' detailed report:

Seattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Full Year 2018 Financial Results On February 7, 2019

Seattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Full Year 2018 Financial Results On February 7, 2019

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets.

Seattle Genetics Announces Publication Of North American Subgroup Data From ECHELON-1 Phase 3 Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Newly Diagnosed Advanced Hodgkin Lymphoma

Seattle Genetics Announces Publication Of North American Subgroup Data From ECHELON-1 Phase 3 Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Newly Diagnosed Advanced Hodgkin Lymphoma

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the publication of data from the ECHELON-1 phase 3 clinical trial online in the journal Clinical Cancer Research.

Seattle Genetics To Present At The J.P. Morgan Healthcare Conference

Seattle Genetics To Present At The J.P. Morgan Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the 37 th Annual J.

Seattle Genetics And Takeda Present Positive Data From Phase 3 ECHELON-2 Clinical Trial For ADCETRIS® (Brentuximab Vedotin) In Frontline Treatment Of CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics And Takeda Present Positive Data From Phase 3 ECHELON-2 Clinical Trial For ADCETRIS® (Brentuximab Vedotin) In Frontline Treatment Of CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) announced that data from the ECHELON-2 phase 3 clinical trial will be presented today in an oral session at the 60 th American Society of Hematology (ASH) Annual...

Seattle Genetics Highlights Additional Analyses From ECHELON-1 Phase 3 Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Newly Diagnosed Advanced Hodgkin Lymphoma At ASH Annual Meeting

Seattle Genetics Highlights Additional Analyses From ECHELON-1 Phase 3 Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Newly Diagnosed Advanced Hodgkin Lymphoma At ASH Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from the ECHELON-1 phase 3 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with AVD (Adriamycin ®, vinblastine and dacarbazine) in newly diagnosed stage III or IV...

Seattle Genetics Highlights Multiple Data Sets Evaluating The Combination Of ADCETRIS® (Brentuximab Vedotin) And Opdivo® (Nivolumab) At ASH Annual Meeting

Seattle Genetics Highlights Multiple Data Sets Evaluating The Combination Of ADCETRIS® (Brentuximab Vedotin) And Opdivo® (Nivolumab) At ASH Annual Meeting

Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from three ongoing clinical trials evaluating the combination of ADCETRIS (brentuximab vedotin) and Opdivo (nivolumab) at the 60 th American Society of Hematology (ASH) Annual Meeting and...

Seattle Genetics To Webcast Investor And Analyst Event At American Society Of Hematology Annual Meeting

Seattle Genetics To Webcast Investor And Analyst Event At American Society Of Hematology Annual Meeting

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 3, 2018 during the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, Calif.

Seattle Genetics Announces FDA Approval Of ADCETRIS® (Brentuximab Vedotin) In Combination With Chemotherapy For Adults With Previously Untreated Systemic Anaplastic Large Cell Lymphoma Or Other CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics Announces FDA Approval Of ADCETRIS® (Brentuximab Vedotin) In Combination With Chemotherapy For Adults With Previously Untreated Systemic Anaplastic Large Cell Lymphoma Or Other CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for ADCETRIS ® (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.

FDA Grants Breakthrough Therapy Designation To ADCETRIS® (Brentuximab Vedotin) For Frontline Peripheral T-Cell Lymphomas

FDA Grants Breakthrough Therapy Designation To ADCETRIS® (Brentuximab Vedotin) For Frontline Peripheral T-Cell Lymphomas

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.

TheStreet Quant Rating: C- (Hold)